State-of-the-Art Imaging in Cardiac Oncology
- 10 Downloads
Purpose of Review
Imaging modalities play an important role in the diagnosis and management of cardiotoxicity and cardiac tumors. In this review, we provide an overview of the imaging modalities that are relevant to the field of cardio-oncology.
Cardiac magnetic resonance provides comprehensive tissue characterization in the assessment of cardiac tumors and cardiomyopathy. The combination of positron emission tomography/computed tomography offers improved localization of lesions, staging, targeting of biopsy and therapy, and greater confidence in interpretation.
Overall, cardiac imaging plays a critical role in the assessment and management of cardiac tumors either for surgical planning or for initiation of appropriate cancer therapies. For certain higher risk cancer patients and survivors, routine surveillance with cardiac imaging may be warranted so appropriate interventions can be instituted to stabilize or even improve the cardiac dysfunction.
KeywordsCardio-oncology Cardiovascular imaging Cardiac imaging Cardiac magnetic resonance
Compliance with Ethical Guidelines
Conflict of interest
Pratik Patel and Suma Konety each declare no potential conflicts of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Recently published papers of particular interest have been highlighted as: • Of importance
- 4.• Tamene AM, Masri C, Konety SH. Cardiovascular MR imaging in cardio-oncology. Magn Reson Imaging Clin N Am. 2015;23(1):105–16. This is an excellent review paper that highlights the important role of cardiac MRI in evaluation of cardiac masses and monitoring of cancer therapy related cadiotoxicty. Google Scholar
- 5.• Motwani M, Kidambi A, Herzog BA, Uddin A, Greenwood JP, Plein S. MR imaging of cardiac tumors and masses: a review of methods and clinical applications. Radiology. 2013;268(1):26–43. This review article describes various MRI sequences used to analyze a cardiac mass. Google Scholar
- 9.• Hoffmann U, Globits S, Schima W, Loewe C, Puig S, Oberhuber G, et al. Usefulness of magnetic resonance imaging of cardiac and paracardiac masses. Am J Cardiol. 2003;92(7):890–5. This study demonstrated that certain MRI features differentiated benign vs malignant nature of a cardiac mass. Google Scholar
- 10.• Pazos-López P, Pozo E, Siqueira ME, García-Lunar I, Cham M, Jacobi A, et al. Value of CMR for the differential diagnosis of cardiac masses. JACC Cardiovasc Imaging. 2014;7(9):896–905. This study also demonstrated that certain MRI features differentiated benign vs malignant nature of a cardiac mass. Google Scholar
- 12.• Patel R, Lim RP, Saric M, Nayar A, Babb J, Ettel M, et al. Diagnostic performance of cardiac magnetic resonance imaging and echocardiography in evaluation of cardiac and paracardiac masses. Am J Cardiol. 2016;117(1):135–40. This study demonstrated that MRI had higher correlation with histopathological diagnosis of a cardiac mass than echo. 45 out of 65 patients had histopathologic diagnosis of cardiac mass. Google Scholar
- 14.• Rahbar K, Seifarth H, Schäfers M, Stegger L, Hoffmeier A, Spieker T, et al. Differentiation of malignant and benign cardiac tumors using 18F-FDG PET/CT. J Nucl Med. 2012;53(6):856–63. PET-CT differentiated benign vs malignant nature of a cardiac mass. Google Scholar
- 18.• Nensa F, Tezgah E, Poeppel TD, Jensen CJ, Schelhorn J, Köhler J, et al. Integrated 18F-FDG PET/MR imaging in the assessment of cardiac masses: a pilot study. J Nucl Med. 2015;56(2):255–60. PET-MRI differentiated benign vs malignant nature of a cardiac mass. Google Scholar
- 24.• van Rosendael AR, Daniëls LA, Dimitriu-Leen AC, Smit JM, van Rosendael PJ, Schalij MJ, et al. Different manifestation of irradiation induced coronary artery disease detected with coronary computed tomography compared with matched non-irradiated controls. Radiother Oncol. 2017;125(1):55–61. This study demonstrated that coronary CTA can be used to screen for significant CAD in long term survivors of lymphoma who received prior radiation therapy. Google Scholar
- 28.Plana JC, Galderisi M, Barac A, Ewer MS, Ky B, Scherrer-Crosbie M, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2014;27(9):911–39.PubMedCrossRefGoogle Scholar
- 29.Tan-Chiu E, Yothers G, Romond E, Geyer CE, Ewer M, Keefe D, et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol. 2005;23(31):7811–9.PubMedCrossRefGoogle Scholar
- 30.Sawaya H, Sebag IA, Plana JC, Januzzi JL, Ky B, Tan TC, et al. Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab. Circ Cardiovasc Imaging. 2012;5(5):596–603.PubMedPubMedCentralCrossRefGoogle Scholar
- 32.• Ali MT, Yucel E, Bouras S, Wang L, Fei HW, Halpern EF, et al. Myocardial Strain Is Associated with Adverse Clinical Cardiac Events in Patients Treated with Anthracyclines. J Am Soc Echocardiogr. 2016;29(6):522–7. This study demostrated that abnormal myocardial strain at baseline was associated with higher incidence of cardiac death and heart failure over ~ 4 years. Google Scholar
- 33.• Rhea IB, Uppuluri S, Sawada S, Schneider BP, Feigenbaum H. Incremental prognostic value of echocardiographic strain and its association with mortality in cancer patients. J Am Soc Echocardiogr. 2015;28(6):667–73. This study demonstrated that abnormal strain at baseline was associated with increased all-cause mortality over ~ 2 years. Google Scholar
- 36.Bellenger NG, Burgess MI, Ray SG, Lahiri A, Coats AJ, Cleland JG, et al. Comparison of left ventricular ejection fraction and volumes in heart failure by echocardiography, radionuclide ventriculography and cardiovascular magnetic resonance; are they interchangeable? Eur Heart J. 2000;21(16):1387–96.PubMedCrossRefGoogle Scholar
- 39.Gulati G, Heck SL, Ree AH, Hoffmann P, Schulz-Menger J, Fagerland MW, et al. Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. Eur Heart J. 2016;37(21):1671–80.PubMedPubMedCentralCrossRefGoogle Scholar
- 40.Pituskin E, Mackey JR, Koshman S, Jassal D, Pitz M, Haykowsky MJ, et al. Multidisciplinary approach to novel therapies in cardio-oncology research (MANTICORE 101-Breast): a randomized trial for the prevention of trastuzumab-associated cardiotoxicity. J Clin Oncol. 2017;35(8):870–7.PubMedCrossRefGoogle Scholar
- 43.Nakano S, Takahashi M, Kimura F, Senoo T, Saeki T, Ueda S, et al. Cardiac magnetic resonance imaging-based myocardial strain study for evaluation of cardiotoxicity in breast cancer patients treated with trastuzumab: a pilot study to evaluate the feasibility of the method. Cardiol J. 2016;23(3):270–80.PubMedCrossRefGoogle Scholar
- 45.Drafts BC, Twomley KM, D’Agostino R, Lawrence J, Avis N, Ellis LR, et al. Low to moderate dose anthracycline-based chemotherapy is associated with early noninvasive imaging evidence of subclinical cardiovascular disease. JACC Cardiovasc Imaging. 2013;6(8):877–85.PubMedPubMedCentralCrossRefGoogle Scholar
- 47.• Armstrong GT, Plana JC, Zhang N, Srivastava D, Green DM, Ness KK, et al. Screening adult survivors of childhood cancer for cardiomyopathy: comparison of echocardiography and cardiac magnetic resonance imaging. J Clin Oncol. 2012;30(23):2876–84. MRI classified adult surviors of childhood cancer with LVEF < 50% better than echo. Google Scholar